Literature DB >> 19686693

Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin.

Chunmei Cheng1, Ilham Bettahi, Maria I Cruz-Fisher, Sukumar Pal, Pooja Jain, Zhenyu Jia, Jan Holmgren, Ali M Harandi, Luis M de la Maza.   

Abstract

The present study was undertaken to test the efficacy of immunization with the native major outer membrane protein (nMOMP) of Chlamydia trachomatis mouse pneumonitis (MoPn) serovar in combination with a novel immunostimulatory adjuvant consisting of CpG oligodeoxynucleotide (ODN) linked to the nontoxic B subunit of cholera toxin (CTB-CpG) to elicit a protective immune response to C. trachomatis. High levels of Chlamydia-specific IgG antibodies were detected in the sera from BALB/c mice immunized intramuscularly and subcutaneously (i.m.+s.c.) with the nMOMP/CTB-CpG vaccine or with nMOMP adjuvanted with a mixture of CT and CpG ODN (CT+CpG). Further, these immunization schemes gave rise to significant T-cell-mediated Chlamydia-specific immune responses. No Chlamydia-specific humoral or cell-mediated immune responses were detected in the control mice vaccinated with ovalbumin together with either CTB-CpG or CT+CpG. Following an intranasal challenge with C. trachomatis the groups of mice immunized with nMOMP plus CTB-CpG, CT+CpG or live C. trachomatis were found to be protected based on their change in body weight and lung weight as well as number of inclusion forming unit recovered from the lungs, as compared with control groups immunized with ovalbumin plus either adjuvants. Interestingly, IFN-gamma-producing CD4(+), but not CD8(+), T-cells showed a significant correlation with the outcomes of the challenge. In conclusion, nMOMP in combination with the novel adjuvant CTB-CpG elicited a significant antigen-specific antibody and cell-mediated immune responses as well as protection against a pulmonary challenge with C. trachomatis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19686693      PMCID: PMC3566636          DOI: 10.1016/j.vaccine.2009.07.108

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  47 in total

1.  Antigen-specific CD8+ T cells respond to Chlamydia trachomatis in the genital mucosa.

Authors:  Nadia R Roan; Michael N Starnbach
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4.

Authors:  M Marinaro; H F Staats; T Hiroi; R J Jackson; M Coste; P N Boyaka; N Okahashi; M Yamamoto; H Kiyono; H Bluethmann; K Fujihashi; J R McGhee
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

3.  Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.

Authors:  Sukumar Pal; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Synthetic peptides based on Chlamydia trachomatis antigens identify cytotoxic T lymphocyte responses in subjects from a trachoma-endemic population.

Authors:  M J Holland; D J Conway; T J Blanchard; O M Mahdi; R L Bailey; H C Whittle; D C Mabey
Journal:  Clin Exp Immunol       Date:  1997-01       Impact factor: 4.330

Review 5.  Chlamydia vaccines: strategies and status.

Authors:  Joseph U Igietseme; Carolyn M Black; Harlan D Caldwell
Journal:  BioDrugs       Date:  2002       Impact factor: 5.807

6.  Vaccination of newborn mice induces a strong protective immune response against respiratory and genital challenges with Chlamydia trachomatis.

Authors:  Sukumar Pal; Ellena M Peterson; Luis M de la Maza
Journal:  Vaccine       Date:  2005-07-19       Impact factor: 3.641

7.  Clearance of Chlamydia trachomatis from the murine genital mucosa does not require perforin-mediated cytolysis or Fas-mediated apoptosis.

Authors:  L L Perry; K Feilzer; S Hughes; H D Caldwell
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

8.  Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin.

Authors:  Jenni Adamsson; Marianne Lindblad; Annika Lundqvist; Denise Kelly; Jan Holmgren; Ali M Harandi
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

9.  Prevalence of chlamydial and gonococcal infections among young adults in the United States.

Authors:  William C Miller; Carol A Ford; Martina Morris; Mark S Handcock; John L Schmitz; Marcia M Hobbs; Myron S Cohen; Kathleen Mullan Harris; J Richard Udry
Journal:  JAMA       Date:  2004-05-12       Impact factor: 56.272

Review 10.  CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.

Authors:  Ali M Harandi; Jan Holmgren
Journal:  Curr Opin Investig Drugs       Date:  2004-02
View more
  16 in total

1.  Induction of immune memory by a multisubunit chlamydial vaccine.

Authors:  F O Eko; E Ekong; Q He; C M Black; J U Igietseme
Journal:  Vaccine       Date:  2010-12-22       Impact factor: 3.641

2.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

3.  Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model.

Authors:  Chunmei Cheng; Sukumar Pal; Ilham Bettahi; Kristie L Oxford; Peter A Barry; Luis M de la Maza
Journal:  Vaccine       Date:  2011-03-04       Impact factor: 3.641

4.  A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.

Authors:  Chunmei Cheng; Pooja Jain; Ilham Bettahi; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-07-08       Impact factor: 3.641

Review 5.  Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Authors:  Sam Vasilevsky; Gilbert Greub; Denise Nardelli-Haefliger; David Baud
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

6.  Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model.

Authors:  Qing Pan; Roshan Pais; Adaugo Ohandjo; Cheng He; Qing He; Yusuf Omosun; J U Igietseme; F O Eko
Journal:  Vaccine       Date:  2015-02-17       Impact factor: 3.641

7.  A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.

Authors:  Chunmei Cheng; Sukumar Pal; Delia Tifrea; Zhenyu Jia; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-11-27       Impact factor: 2.700

8.  Computational modeling of TC0583 as a putative component of the Chlamydia muridarum V-type ATP synthase complex and assessment of its protective capabilities as a vaccine antigen.

Authors:  Delia F Tifrea; Michael L Barta; Sukumar Pal; P Scott Hefty; Luis M de la Maza
Journal:  Microbes Infect       Date:  2015-12-17       Impact factor: 2.700

9.  Assessment of the role in protection and pathogenesis of the Chlamydia muridarum V-type ATP synthase subunit A (AtpA) (TC0582).

Authors:  Chunmei Cheng; Pooja Jain; Sukumar Pal; Delia Tifrea; Guifeng Sun; Andy A Teng; Xiaowu Liang; Philip L Felgner; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-10-23       Impact factor: 2.700

10.  Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge.

Authors:  Zonghui Zuo; Yongjuan Zou; Qiang Li; Yongxia Guo; Tianyuan Zhang; Jie Wu; Cheng He; Francis O Eko
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.